Novo Nordisk Faces Downgrade and Stock Decline Amid Trial SetbacksHSBC downgrades Novo Nordisk (NYSE:NVO) from "Buy" to "Hold" as the stock nears a four-year low.Significant stock price decline follows disappointing trial data for Alzheimer's drug, semaglutide.Despite the challenges, there is notable activity among call traders, indicating some investor optimism.Novo Nordisk (NYSE:NVO), a leading global healthcare company renowned for its diabetes and obesity treatments, has recently experienced a downgrade ...